Show simple item record

dc.rights.licenseopenen_US
dc.contributor.authorDYBJER, E.
dc.contributor.authorENGSTROM, G.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHELMER, Catherine
dc.contributor.authorNAGGA, K.
dc.contributor.authorRORSMAN, P.
dc.contributor.authorNILSSON, P. M.
dc.date.accessioned2021-01-22T14:51:25Z
dc.date.available2021-01-22T14:51:25Z
dc.date.issued2020
dc.identifier.issn1464-5491 (Electronic) 0742-3071 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/25963
dc.description.abstractEnAim The aim of this observational study was to investigate relationships between physiological levels of glucometabolic biomarkers and cognitive test results in a population‐based setting. Methods Cross‐sectional data were obtained from the Swedish population‐based Malmö Diet and Cancer Study Re‐examination 2007–2012 comprising 3001 older people (mean age 72 years). Through oral glucose tolerance testing (OGTT), fasting and post‐load levels of serum insulin, plasma glucagon, serum glucose‐dependent insulinotropic peptide (GIP) and plasma glucagon‐like peptide‐1 (GLP‐1) were measured. Insulin resistance and insulin sensitivity levels were calculated. In 454 participants, advanced glycation end products (AGEs) were estimated through skin autofluorescence. Associations between biomarkers and two cognitive tests, the Mini‐Mental State Examination (MMSE) and A Quick Test of Cognitive Speed (AQT) respectively, were explored in multiple regression analyses. Results Positive associations following adjustments for known prognostic factors were found between MMSE scores and insulin sensitivity (B = 0.822, P = 0.004), 2‐h plasma glucagon (B = 0.596, P = 0.026), 2‐h serum GIP (B = 0.581, P = 0.040) and 2‐h plasma GLP‐1 (B = 0.585, P = 0.038), whereas negative associations were found between MMSE scores and insulin resistance (B = −0.734, P = 0.006), fasting plasma GLP‐1 (B = −0.544, P = 0.033) and AGEs (B = −1.459, P = 0.030) were found. Conclusions Higher levels of insulin sensitivity, GIP and GLP‐1 were associated with better cognitive outcomes, but AGEs were associated with worse outcomes, supporting evidence from preclinical studies. Glucagon was linked to better outcomes, which could possibly reflect neuroprotective properties similar to the related biomarker GLP‐1 which has similar intracellular properties. Longitudinal and interventional studies are needed to further evaluate neuromodulating effects of these biomarkers.
dc.language.isoENen_US
dc.subjectLEHA
dc.title.enIncretin hormones, insulin, glucagon and advanced glycation end products in relation to cognitive function in older people with and without diabetes, a population-based study
dc.title.alternativeDiabet Meden_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/dme.14267en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32020688en_US
bordeaux.journalDiabetic Medicineen_US
bordeaux.page1157-1166en_US
bordeaux.volume37en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue7en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03118832
hal.version1
hal.date.transferred2021-01-22T14:51:29Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Diabetic%20Medicine&rft.date=2020&rft.volume=37&rft.issue=7&rft.spage=1157-1166&rft.epage=1157-1166&rft.eissn=1464-5491%20(Electronic)%200742-3071%20(Linking)&rft.issn=1464-5491%20(Electronic)%200742-3071%20(Linking)&rft.au=DYBJER,%20E.&ENGSTROM,%20G.&HELMER,%20Catherine&NAGGA,%20K.&RORSMAN,%20P.&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record